^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Phase I study of Minnelide and paclitaxel combination chemotherapy in refractory gastric cancer (GC).

Published date:
01/17/2023
Excerpt:
In all, 3 patients had HER2 positive GC and 10 patients had PDL1 + tumor. In the monotherapy cohorts, there were no DLTs observed, and the regimen was tolerated well. One patient achieved confirmed PR which lasted for 6 months. For the combination arm (cohort D-F), there were no DLTs observed...Minnelide in combination with weekly paclitaxel demonstrated promising anti-tumor activity with durable responses in refractory AGC.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2023.41.3_suppl.414